SpringWorks Therapeutics is a US-based biopharmaceutical company of Merck KGaA, Darmstadt, Germany, dedicated to developing innovative treatments for patients with rare tumors.

We’ve achieved FDA and EC approval for the first and only medicines for adults with desmoid tumors and the first and only medicines for both adults and children with neurofibromatosis type 1 associated plexiform neurofibromas (NF1-PN).

At SpringWorks, we’re driven by a commitment to finding answers for those facing rare diseases, fueled by a culture of urgency and tenacity. Our focus is on BCMA combinations in multiple myeloma and we are actively engaged in investigator-initiated research to unlock the full potential of targeted oncology.

We value authenticity and diversity, recognizing that a wide range of perspectives is essential to our mission of improving patient outcomes.

EZMEKLY® (mirdametinib) | SpringWorks Therapeutics

Product description

SpringWorks Therapeutics Stamford, United States (US)

Price: N/A

SpringWorks Therapeutics
Stamford, United States (US)